WEBSITE BSE:524652 NSE: IND.SWIFT LT Inc. Year: 1986 Industry: Pharmaceuticals & Drugs My Bucket: Add Stock
Last updated: 00:00
No Notes Added Yet
Established in 1986 by Mr. Gopal Munjal, Ind-Swift Limited is a prominent pharmaceutical company in India. The company manufactures and markets a wide range of pharmaceutical products, including active pharmaceutical ingredients (APIs), formulations, and nutraceuticals. Ind-Swift's clientele includes healthcare providers, hospitals, and pharmacies both domestically and internationally. Promoted by Munjal family, company's mission is to provide high-quality pharmaceutical products that improve patient health and well-being. Ind-Swift's state-of-...Read More
Established in 1986 by Mr. Gopal Munjal, Ind-Swift Limited is a prominent pharmaceutical company in India. The company manufactures and markets a wide range of pharmaceutical products, including active pharmaceutical ingredients (APIs), formulations, and nutraceuticals. Ind-Swift's clientele includes healthcare providers, hospitals, and pharmacies both domestically and internationally. Promoted by Munjal family, company's mission is to provide high-quality pharmaceutical products that improve patient health and well-being. Ind-Swift's state-of-the-art manufacturing facilities, stringent quality control measures, and dedicated R&D team ensure the production of premium pharmaceutical products that meet international standards. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹85 Cr.
Stock P/E 6
P/B -0.2
Current Price ₹15.7
Book Value ₹ -75.2
Face Value 2
52W High ₹19.9
Dividend Yield 0%
52W Low ₹ 12
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 107 | 106 | 149 | 116 | 103 | 135 | 114 | 136 | 120 | 145 |
| Other Income | 3 | 6 | 6 | 3 | 3 | 46 | 40 | 5 | 3 | 9 |
| Total Income | 110 | 112 | 154 | 119 | 105 | 181 | 154 | 141 | 123 | 154 |
| Total Expenditure | 89 | 98 | 130 | 105 | 98 | 121 | 111 | 122 | 113 | 148 |
| Operating Profit | 21 | 14 | 24 | 14 | 7 | 61 | 43 | 19 | 10 | 6 |
| Interest | 15 | 14 | 15 | 18 | 15 | 14 | 10 | 10 | 10 | 10 |
| Depreciation | 7 | 7 | 7 | 7 | 7 | 7 | 5 | 5 | 6 | 7 |
| Exceptional Income / Expenses | 0 | 61 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 273 |
| Profit Before Tax | -1 | 53 | 2 | -11 | -15 | 40 | 28 | 4 | -5 | 261 |
| Provision for Tax | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 4 |
| Profit After Tax | -1 | 53 | 2 | -11 | -15 | 38 | 28 | 4 | -5 | 257 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 |
| Profit After Adjustments | -1 | 53 | 2 | -11 | -15 | 38 | 28 | 4 | -5 | 257 |
| Adjusted Earnings Per Share | -0.2 | 9.8 | 0.4 | -2 | -2.8 | 6.9 | 5.2 | 0.8 | -1 | 47.4 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2022 | Mar 2023 | Mar 2024 | TTM |
|---|---|---|---|---|---|---|---|
| Net Sales | 304 | 263 | 270 | 398 | 411 | 502 | 515 |
| Other Income | 13 | 14 | 15 | 24 | 12 | 58 | 57 |
| Total Income | 317 | 277 | 284 | 421 | 423 | 560 | 572 |
| Total Expenditure | 461 | 328 | 264 | 352 | 369 | 454 | 494 |
| Operating Profit | -144 | -52 | 21 | 69 | 54 | 107 | 78 |
| Interest | 19 | 16 | 11 | 57 | 60 | 63 | 40 |
| Depreciation | 36 | 36 | 35 | 32 | 29 | 27 | 23 |
| Exceptional Income / Expenses | 0 | -260 | -28 | 1 | 61 | 0 | 273 |
| Profit Before Tax | -200 | -363 | -53 | -20 | 26 | 16 | 288 |
| Provision for Tax | 0 | 1 | 1 | 0 | 0 | 2 | 4 |
| Profit After Tax | -200 | -364 | -54 | -20 | 26 | 14 | 284 |
| Adjustments | -14 | -8 | 4 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | -214 | -373 | -50 | -20 | 26 | 14 | 284 |
| Adjusted Earnings Per Share | -42.4 | -68.8 | -9.3 | -3.7 | 4.8 | 2.6 | 52.4 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 22% | 23% | 11% | 0% |
| Operating Profit CAGR | 98% | 72% | 0% | 0% |
| PAT CAGR | -46% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 20% | 22% | 31% | 13% |
| ROE Average | 0% | 0% | 0% | 0% |
| ROCE Average | 26% | 22% | -0% | -4% |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|
| Shareholder's Funds | -245 | -616 | -663 | -720 | -705 | -691 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 672 | 665 | 667 | 619 | 403 | 1010 |
| Other Non-Current Liabilities | 8 | 7 | 13 | 15 | 14 | 15 |
| Total Current Liabilities | 621 | 608 | 598 | 718 | 936 | 320 |
| Total Liabilities | 1055 | 665 | 615 | 632 | 649 | 654 |
| Fixed Assets | 374 | 342 | 311 | 236 | 216 | 184 |
| Other Non-Current Assets | 59 | 116 | 118 | 154 | 159 | 129 |
| Total Current Assets | 612 | 206 | 186 | 242 | 273 | 342 |
| Total Assets | 1055 | 665 | 615 | 632 | 649 | 654 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 17 | 17 | 9 | 29 | 16 | 13 |
| Cash Flow from Operating Activities | -119 | -2 | 7 | 50 | 73 | 15 |
| Cash Flow from Investing Activities | 10 | 4 | -6 | -18 | -29 | 77 |
| Cash Flow from Financing Activities | 110 | -11 | -6 | -45 | -47 | -42 |
| Net Cash Inflow / Outflow | 0 | -8 | -5 | -13 | -3 | 50 |
| Closing Cash & Cash Equivalent | 17 | 9 | 4 | 16 | 13 | 63 |
| # | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | -42.42 | -68.81 | -9.31 | -3.7 | 4.81 | 2.63 |
| CEPS(Rs) | -32.49 | -60.66 | -3.6 | 2.23 | 10.1 | 7.63 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | -54.86 | -116.26 | -125.06 | -132.99 | -130.1 | -127.54 |
| Core EBITDA Margin(%) | -51 | -24.48 | 2.33 | 11.22 | 10.04 | 9.18 |
| EBIT Margin(%) | -58.75 | -129.89 | -15.49 | 9.29 | 20.5 | 15.02 |
| Pre Tax Margin(%) | -64.91 | -135.99 | -19.73 | -4.85 | 6.22 | 3.11 |
| PAT Margin (%) | -64.97 | -136.33 | -20.01 | -4.95 | 6.22 | 2.69 |
| Cash Profit Margin (%) | -53.16 | -122.95 | -7.21 | 2.98 | 13.07 | 7.82 |
| ROA(%) | -18.95 | -42.37 | -8.46 | -3.21 | 4.07 | 2.18 |
| ROE(%) | 0 | 0 | 0 | 0 | 0 | 0 |
| ROCE(%) | -22.84 | -56.7 | -10.34 | 10.83 | 28.45 | 25.99 |
| Receivable days | 451.08 | 333.86 | 129.49 | 78.62 | 85.13 | 88.62 |
| Inventory Days | 107.86 | 88.79 | 56.99 | 51.94 | 69.31 | 52.96 |
| Payable days | 290.34 | 370.59 | 388.38 | 320.17 | 367.14 | 283.39 |
| PER(x) | 0 | 0 | 0 | 0 | 1.5 | 6.97 |
| Price/Book(x) | -0.1 | -0.05 | -0.06 | -0.08 | -0.06 | -0.14 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 3.52 | 4.12 | 4.04 | 2.72 | 2.48 | 2.09 |
| EV/Core EBITDA(x) | -7.41 | -20.96 | 52.27 | 15.68 | 18.9 | 9.86 |
| Net Sales Growth(%) | 0 | -13.56 | 2.57 | 47.4 | 3.33 | 22.21 |
| EBIT Growth(%) | 0 | -91.96 | 87.92 | 189.6 | 128.45 | -7.46 |
| PAT Growth(%) | 0 | -82.19 | 85.14 | 63.01 | 230.05 | -45.34 |
| EPS Growth(%) | 0 | -62.2 | 86.47 | 60.3 | 230.05 | -45.34 |
| Debt/Equity(x) | -4 | -1.7 | -1.57 | -1.44 | -1.41 | -1.47 |
| Current Ratio(x) | 0.99 | 0.34 | 0.31 | 0.34 | 0.29 | 1.07 |
| Quick Ratio(x) | 0.84 | 0.28 | 0.24 | 0.24 | 0.2 | 0.87 |
| Interest Cover(x) | -9.53 | -21.27 | -3.66 | 0.66 | 1.44 | 1.26 |
| Total Debt/Mcap(x) | 38.57 | 34.44 | 26.62 | 17.09 | 25.38 | 10.23 |
| # | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 55.58 | 55.58 | 55.58 | 55.58 | 55.58 | 55.58 | 55.58 | 55.58 | 55.58 | 55.58 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 44.42 | 44.42 | 44.42 | 44.42 | 44.42 | 44.42 | 44.42 | 44.42 | 44.42 | 44.42 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 2.41 | 2.41 | 2.41 | 2.41 | 2.41 | 2.41 | 2.41 | 2.41 | 2.41 | 2.41 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
